secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016890
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics Q2 net loss widens to $28.1M; cash runway into 2025; expands 4D-310 trial to females
--------------------------------------------------------------------------------

- Net loss of $28.1M in Q2 2022 vs $7.6M in Q2 2021; revenue fell to $0.2M from $14.6M.
- Cash and equivalents of $261.6M as of June 30, 2022, expected to fund operations into first half 2025.
- R&D expenses rose to $20.4M from $15.2M; G&A to $8.2M from $7.0M.
- 4D-310 Phase 1/2 expanded to include female Fabry patients; new steroid-sparing immunosuppression cohort added; data update expected 1H 2023.
- Five clinical-stage candidates on track for multiple clinical data updates in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017022016890/0000950170-22-016890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017022016890/fdmt-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer